Objective To conduct a comprehensive survey of the resource allocation and radiological diagnosis frequency in radiological diagnosis and treatment institutions in Shaanxi Province, and provide scientific evidence for optimizing regional medical resource allocation and formulating radiation protection strategies. Methods In 2022, a cross-sectional survey was conducted on 1564 radiological diagnosis and treatment institutions in Shaanxi Province (excluding dental clinics and military/armed police force hospitals). Data on equipment configuration, personnel distribution, and number of diagnostic examinations were collected. Results There were a total of 8798 radiation workers engaged in radiological diagnosis and 3617 X-ray diagnostic units in Shaanxi Province. Moreover, 35.8% (3151) of the radiation workers and 21.9% (792) of the radiological diagnostic units were in tertiary hospitals. There were 91.5 X-ray diagnostic units per million population, including 53.2 X-ray radiography units and 17.1 computed tomography (CT) units per million population. In 2022, the total number of X-ray diagnostic examinations was 21 303 635, primarily including 10 812 197 (50.8%) X-ray radiography examinations and 8 969 358 (42.1%) CT examinations. Analysis of equipment utilization intensity showed that the average annual number of examinations per unit of radiological diagnostic equipment in tertiary hospitals reached 10 506.1, with CT equipment bearing the most prominent workload (13 248.7 examinations/unit). The overall radiological diagnosis frequency was 538.8 examinations/thousand population (273.4 X-ray radiography and 226.8 CT examinations/thousand population). Tertiary, secondary, and primary and below institutions accounted for 39.1%, 44.0%, and 16.9% of the total number of examinations, respectively. Conclusion The radiological diagnosis frequency in Shaanxi Province (538.8 examinations/thousand population) was below the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) Healthcare Level I (823 examinations/thousand population). Issues such as uneven resource distribution and CT equipment overload should be addressed by digital upgrading, hierarchical diagnosis and treatment systems, and enhanced equipment maintenance.

Objective To establish baseline radiation dose data for computed tomography (CT) examinations in Shaanxi Province, China and to provide scientific evidence for optimizing medical radiation protection. Methods From 2020 to 2023, a multicenter cross-sectional study was conducted using 16 CT scanners across 9 hospitals (2 specialized pediatric hospitals and 7 general hospitals). Standardized registration forms were used to collect basic information (e.g., age and examination site), scanning parameters (e.g., tube voltage, tube current-time product, and scan length), and dosimetric parameters (volume CT dose index [CTDI_vol] and dose-length product [DLP]). Non-parametric tests were employed for intergroup comparisons. Results A significant positive correlation was observed between age and major CT scanning parameters. Both CTDI_vol and DLP increased significantly with age across all examination sites (P < 0.001). Abdominal CTDI_vol was significantly lower in specialized pediatric hospitals than in general hospitals (8.0 vs. 15.5 mGy, P < 0.001). The < 1-year age group showed higher abdominal CTDI_vol (13.2 vs. 8.6 mGy) but lower DLP (243.5 vs. 261.9 mGy·cm) compared to the 1- < 5-year group. Conclusion This study established the first baseline radiation dose database for CT examinations in Shaanxi Province, providing critical scientific support for developing regional diagnostic reference levels and optimizing radiological protection practices.

Objective To observe the effectiveness and safety of netupitant/palonosetron in the treat-ment of chemotherapy-induced nausea and vomiting(CINV)in hematologic tumor patients undergoing autol-ogous and allogeneic stem cell transplantation.Methods Adult hematologic tumor patients who received net-upitant/palonosetron to prevent chemotherapy-induced nausea and vomiting CINV during pre-transplant chemotherapy at West China Hospital of Sichuan University from January to September 2022 were collected.On the first and third day of pre-transplant chemotherapy,netupitant/palonosetron was orally administered one hour before the infusion of pre-transplant chemotherapy drugs,for a total of two doses.The nausea and CINV status of the patients from the start of pre-transplant chemotherapy to 7 days after stem cell infusion were recorded.Results As a result,a total of 125 patients with hematological tumors were included,and the complete remission rates during pre-treatment chemotherapy were 72.8%,80.0%and 66.4%in the acute phase,delayed phase,and total phase,respectively.The rates of no vomiting were 89.6%,92.0%and 72.8%,respectively.The rates of no rescue medication were 95.2%,93.6%and 73.6%,respectively.The complete remission rate of 33 plasma cell tumors and 46 leukemia and myelodysplastic syndrome patients exceeded 70%,and the complete remission rate of 46 lymphoma patients exceeded 90%.The complete response rate in the delayed phase of the pre-treatment CHiGCB regimen(chidamide+busulfan+gemcitabine+cladribine)was 93.5%,which was higher than the complete response rate of the BenMel regimen(bendamustine+mel-phalan)(72.7%)and the CHiFAB regimen(chidamide+busulfan+fludarabine+cytarabine)(71.7%).The complete remission rate during the follow-up period of the CHiGCB regimen was 91.3%,which was higher than that of the CHiFAB regimen(65.2%),with the statistically significance(P<0.05).Conclusion Netu-pitant/palonosetron can effectively control CINV in patients undergoing autologous or allogeneic hematopoiet-ic stem cell transplantation for hematologic tumors.

Renal leiomyosarcoma is an extraordinarily rare malignant neoplasm，accounting for less than 1% of all renal malignancies. The prevention and management of postoperative thrombotic and hemorrhagic complications are pivotal in improving patient outcomes. We presented a case of a 62-year-old female with a giant right renal leiomyosarcoma（FNCLCC grade 3）who underwent preoperative arterial embolization followed by radical nephrectomy. On postoperative day 4，the patient developed deep vein thrombosis of the lower extremities. During subsequent anticoagulation therapy，she experienced a life-threatening complication of subcapsular hepatic hematoma. Discontinuing anticoagulation，bed rest，active blood transfusion，and antibiotic prophylaxis for infection being used as conservative treatment，the patient demonstrated significant clinical improvement and discharged after full recovery.

Objective To investigate the eye lens and hand dose levels of interventional radiology workers in Baoji City, China, and to provide data reference for radiation protection. Methods In two general hospitals, the eye lens and finger doses of 121 interventional radiology workers were monitored between 2021 and 2023. The average annual dose levels and dose distribution were analyzed based on years, job positions, surgical sites, and duties during surgery. Results The average annual dose to the eye lens was 3.36 mSv, with the highest dose of 16.36 mSv. The average annual dose to the fingers was 3.38 mSv, with the highest dose of 17.72 mSv. The average annual dose to the eye lens and fingers decreased from 2021 to 2023. The average annual dose to the eye lens of the interventional surgeons was higher than those of the technicians and nurses, while the average annual dose to the fingers of the interventional surgeons was higher than that of the technicians. The average annual doses to the eye lens and fingers of the first operator were similar to those of the second operator, but both were higher than other personnel involved in the interventional surgery, and the differences were statistically significant (all P < 0.05). There were linear regression relationships between the annual doses to the eye lens and fingers and the effective whole-body dose of the interventional radiology workers. A paired test was conducted on the annual dose to the eye lens and fingers of the interventional workers for different surgical sites. The cardiovascular and peripheral vascular interventional workers had higher average annual doses to the eye lens than to the fingers, the cerebrovascular interventional workers had a higher average annual dose to the fingers than to the eye lens, and the differences were statistically significant. Conclusion The annual doses to the eye lens and fingers of the interventional radiology workers in Baoji City were lower than the national limits. However, some workers showed eye lens annual doses close to the new international standard limit (20 mSv). Special attention should be given to interventional physicians, especially the first and second surgeons.

Background/Aims: Metabolic dysfunction–associated steatotic liver disease (MASLD) is a chronic liver disease characterized by hepatic steatosis. Ubiquitin-specific protease 29 (USP29) plays pivotal roles in hepatic ischemiareperfusion injury and hepatocellular carcinoma, but its role in MASLD remains unexplored. Therefore, the aim of this study was to reveal the effects and underlying mechanisms of USP29 in MASLD progression. Methods: USP29 expression was assessed in liver samples from MASLD patients and mice. The role and molecular mechanism of USP29 in MASLD were assessed in high-fat diet-fed and high-fat/high-cholesterol diet-fed mice and palmitic acid and oleic acid treated hepatocytes. Results: USP29 protein levels were significantly reduced in mice and humans with MASLD. Hepatic steatosis, inflammation and fibrosis were significantly exacerbated by USP29 deletion and relieved by USP29 overexpression. Mechanistically, USP29 significantly activated the expression of genes related to fatty acid β-oxidation (FAO) under metabolic stimulation, directly interacted with long-chain acyl-CoA synthase 5 (ACSL5) and repressed ACSL5 degradation by increasing ACSL5 K48-linked deubiquitination. Moreover, the effect of USP29 on hepatocyte lipid accumulation and MASLD was dependent on ACSL5. Conclusions USP29 functions as a novel negative regulator of MASLD by stabilizing ACSL5 to promote FAO. The activation of the USP29-ACSL5 axis may represent a potential therapeutic strategy for MASLD.

Objective:To explore the clinical manifestations, pathology, and prognosis of hepatic mesenchymal hamartoma (MHL).Methods:Clinical data of 10 MHL patients treated at the First Medical Center of Chinese PLA General Hospital from December 2009 to July 2024 were retrospectively analyzed, including seven males and three females, aged (48±23) years. Patients’ age, gender, clinical manifestations, treatment methods, prognosis, and other clinical data were collected.Results:Among them, four cases presented with upper abdominal distension and pain, while the other six showed no abnormal symptoms. All patients had palpable round masses of varying sizes in the upper abdomen. Nine patients had single lesion, among which five were located in the right hepatic lobe, three in the left hepatic lobe, and one in the caudate lobe. One patient had multiple lesions located in both the left and right anterior lobe. The maximum diameter of lesions ranged from 1.5 to 20.0 cm. Seven cases presented with unilocular cystic-solid masses, and three with multilocular cystic-solid masses, with varying sizes of cystic cavities. Microscopically, the tumors exhibited myxoid stroma with spindle or stellate cells, irregular branching bile ducts, residual hepatocyte islands, and variably sized cystic spaces. Four cases with malignant transformation additionally showed undifferentiated mesenchymal cells with atypia, mitotic figures, tumor giant cells, and eosinophilic cytoplasmic inclusions. Immunohistochemistry indicated tumor tissue exhibited positive expression of hepatocyte marker Hepacyte and negative expression of alpha-fetoprotein. The proliferative bile duct epithelium showed positive expression of CK7, CK19, and CK8/18. The spindle cell area expressed vimentin and SMA, with focal expression of desmin, and a Ki67 proliferation index of 5%. In the region of MHL complicated by undifferentiated embryonal sarcoma, there was positive expression of desmin, myogenin, and myoglobin, with a Ki67 proliferation index as high as 30%, and focal expression of S-100, α1-antitrypsin, and CK. A total of seven patients were followed up. Among them, two patients with MHL accompanied by undifferentiated embryonal sarcoma formation experienced tumor recurrence and metastasis after surgery, one patient died after the operation, and the remaining four patients showed no signs of recurrence or metastasis as of the last follow-up.Conclusion:MHL is a rare benign mesenchymal tumor of the liver, which is clinically and radiologically difficult to distinguish from other hepatic tumors. Definitive diagnosis requires percutaneous biopsy or postoperative pathological examination of the tumor. Patients with non-malignant MHL who undergo surgical treatment generally have a favorable prognosis.

Background/Aims: Metabolic dysfunction–associated steatotic liver disease (MASLD) is a chronic liver disease characterized by hepatic steatosis. Ubiquitin-specific protease 29 (USP29) plays pivotal roles in hepatic ischemiareperfusion injury and hepatocellular carcinoma, but its role in MASLD remains unexplored. Therefore, the aim of this study was to reveal the effects and underlying mechanisms of USP29 in MASLD progression. Methods: USP29 expression was assessed in liver samples from MASLD patients and mice. The role and molecular mechanism of USP29 in MASLD were assessed in high-fat diet-fed and high-fat/high-cholesterol diet-fed mice and palmitic acid and oleic acid treated hepatocytes. Results: USP29 protein levels were significantly reduced in mice and humans with MASLD. Hepatic steatosis, inflammation and fibrosis were significantly exacerbated by USP29 deletion and relieved by USP29 overexpression. Mechanistically, USP29 significantly activated the expression of genes related to fatty acid β-oxidation (FAO) under metabolic stimulation, directly interacted with long-chain acyl-CoA synthase 5 (ACSL5) and repressed ACSL5 degradation by increasing ACSL5 K48-linked deubiquitination. Moreover, the effect of USP29 on hepatocyte lipid accumulation and MASLD was dependent on ACSL5. Conclusions USP29 functions as a novel negative regulator of MASLD by stabilizing ACSL5 to promote FAO. The activation of the USP29-ACSL5 axis may represent a potential therapeutic strategy for MASLD.

Background/Aims: Metabolic dysfunction–associated steatotic liver disease (MASLD) is a chronic liver disease characterized by hepatic steatosis. Ubiquitin-specific protease 29 (USP29) plays pivotal roles in hepatic ischemiareperfusion injury and hepatocellular carcinoma, but its role in MASLD remains unexplored. Therefore, the aim of this study was to reveal the effects and underlying mechanisms of USP29 in MASLD progression. Methods: USP29 expression was assessed in liver samples from MASLD patients and mice. The role and molecular mechanism of USP29 in MASLD were assessed in high-fat diet-fed and high-fat/high-cholesterol diet-fed mice and palmitic acid and oleic acid treated hepatocytes. Results: USP29 protein levels were significantly reduced in mice and humans with MASLD. Hepatic steatosis, inflammation and fibrosis were significantly exacerbated by USP29 deletion and relieved by USP29 overexpression. Mechanistically, USP29 significantly activated the expression of genes related to fatty acid β-oxidation (FAO) under metabolic stimulation, directly interacted with long-chain acyl-CoA synthase 5 (ACSL5) and repressed ACSL5 degradation by increasing ACSL5 K48-linked deubiquitination. Moreover, the effect of USP29 on hepatocyte lipid accumulation and MASLD was dependent on ACSL5. Conclusions USP29 functions as a novel negative regulator of MASLD by stabilizing ACSL5 to promote FAO. The activation of the USP29-ACSL5 axis may represent a potential therapeutic strategy for MASLD.